Predictors of Transition to Psychosis in Individuals at Clinical High Risk.

Clinical high risk Prodrome Psychosis Risk factors Schizophrenia, predictors

Journal

Current psychiatry reports
ISSN: 1535-1645
Titre abrégé: Curr Psychiatry Rep
Pays: United States
ID NLM: 100888960

Informations de publication

Date de publication:
29 04 2019
Historique:
entrez: 1 5 2019
pubmed: 1 5 2019
medline: 23 2 2020
Statut: epublish

Résumé

Current research is examining predictors of the transition to psychosis in youth who are at clinical high risk based on attenuated psychotic symptoms (APS). Determining predictors of the development of psychosis is important for an improved understanding of mechanisms as well as the development of preventative strategies. The purpose is to review the most recent literature identifying predictors of the transition to psychosis in those who are already assessed as being at risk. Multidomain models, in particular, integrated models of symptoms, social functioning, and cognition variables, achieve better predictive performance than individual factors. There are many methodological issues; however, several solutions have now been described in the literature. For youth who already have APS, predicting who may go on to later develop psychosis is possible. Several studies are underway in large consortiums that may overcome some of the methodological concerns and develop improved means of prediction.

Identifiants

pubmed: 31037392
doi: 10.1007/s11920-019-1027-y
pii: 10.1007/s11920-019-1027-y
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

39

Subventions

Organisme : CIHR
Pays : Canada

Références

Psychol Med. 2017 Aug;47(11):1923-1935
pubmed: 28249639
Curr Biol. 2012 Sep 25;22(18):1693-8
pubmed: 22902750
Am J Psychiatry. 2016 Oct 1;173(10):980-988
pubmed: 27363508
Schizophr Bull. 2016 May;42(3):732-43
pubmed: 26591006
Psychol Med. 2017 Jul;47(9):1668-1677
pubmed: 28166863
JAMA Psychiatry. 2016 Dec 1;73(12):1239-1248
pubmed: 27806157
Early Interv Psychiatry. 2018 Dec;12(6):1173-1180
pubmed: 28744989
Am J Psychiatry. 2015 Oct;172(10):986-94
pubmed: 26046336
Schizophr Bull. 2017 Jan;43(1):57-63
pubmed: 27798225
Schizophr Bull. 2014 Jul;40(4):729-36
pubmed: 24860087
Biol Psychol. 2011 Jul;87(3):350-7
pubmed: 21536095
Psychol Med. 2016 Mar;46(4):673-81
pubmed: 26568030
PeerJ. 2016 Oct 19;4:e2582
pubmed: 27781169
Schizophr Res. 2015 Dec;169(1-3):193-198
pubmed: 26585219
Am J Psychiatry. 2017 Nov 1;174(11):1075-1085
pubmed: 27978770
Aust N Z J Psychiatry. 2015 May;49(5):462-70
pubmed: 25425742
Schizophr Res. 2019 Mar;205:10-14
pubmed: 29779964
Arch Gen Psychiatry. 2008 Jan;65(1):28-37
pubmed: 18180426
Curr Opin Psychiatry. 2017 May;30(3):209-219
pubmed: 28212173
Psychol Med. 2015 Oct;45(14):2959-73
pubmed: 26040537
Lancet Psychiatry. 2017 Jan;4(1):63-72
pubmed: 27856396
Psychol Med. 2017 May;47(7):1163-1178
pubmed: 28091343
Schizophr Res. 2019 Dec;214:18-23
pubmed: 28935170
Schizophr Res. 2015 Feb;161(2-3):150-5
pubmed: 25439392
Early Interv Psychiatry. 2014 Feb;8(1):77-81
pubmed: 23773288
Schizophr Res. 2018 May;195:554-559
pubmed: 28823722
Psychiatry Res. 2016 Dec 30;246:188-194
pubmed: 27718468
Psychol Med. 2019 Jul;49(10):1670-1677
pubmed: 30176955
Acta Psychiatr Scand. 2017 Jul;136(1):5-15
pubmed: 28168698
Br J Psychiatry. 2003 Jan;182:71-6
pubmed: 12509322
Early Interv Psychiatry. 2017 Jun;11(3):250-254
pubmed: 26663764
Schizophr Bull. 2017 Mar 1;43(2):293-301
pubmed: 28057720
Schizophr Bull. 2015 Jul;41(4):919-29
pubmed: 25210056
Dev Psychopathol. 2013 Nov;25(4 Pt 1):1171-86
pubmed: 24229556
Br J Psychiatry. 2004 Apr;184:287-8
pubmed: 15056569
Am J Psychiatry. 2016 Oct 1;173(10):989-996
pubmed: 27363511
Br J Psychiatry. 2015 Sep;207(3):198-206
pubmed: 26329563
Schizophr Bull. 1982;8(3):470-84
pubmed: 7134891
Psychiatry Res. 2017 Jan;247:55-62
pubmed: 27863320
JAMA Psychiatry. 2015 Sep;72(9):863-4
pubmed: 26266967
Schizophr Res. 2018 May;195:549-553
pubmed: 28935167
Schizophr Res. 2017 Jun;184:32-38
pubmed: 27923525
Schizophr Res. 2015 Feb;161(2-3):143-9
pubmed: 25499046
Neurosci Biobehav Rev. 2015 Oct;57:199-208
pubmed: 26365107
Schizophr Res. 2015 Dec;169(1-3):209-213
pubmed: 26589390
Psychol Med. 2015 Mar;45(4):727-34
pubmed: 25084213
Psychopathology. 2015;48(2):120-6
pubmed: 25720419
Soc Psychiatry Psychiatr Epidemiol. 2016 Apr;51(4):497-503
pubmed: 26851943
Psychol Med. 2016 Jul;46(9):1839-51
pubmed: 26979398
Nat Commun. 2018 Sep 21;9(1):3836
pubmed: 30242220
JAMA Psychiatry. 2018 Sep 1;75(9):960-968
pubmed: 29971330
J Psychiatr Res. 2015 Jun;65:115-23
pubmed: 25837413
Psychol Med. 2019 May;49(7):1128-1137
pubmed: 29950184
Early Interv Psychiatry. 2018 Apr;12(2):115-124
pubmed: 28560861
PLoS One. 2015 Oct 28;10(10):e0141075
pubmed: 26510175
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
World J Biol Psychiatry. 2016 Jun;17(4):285-95
pubmed: 26453061
Psychol Med. 2019 Sep;49(12):1990-1998
pubmed: 30213278
Schizophr Bull. 2019 Jun 18;45(4):924-933
pubmed: 30215784
Int J Methods Psychiatr Res. 2018 Mar;27(1):
pubmed: 28944523
Neuropsychopharmacology. 2016 Feb;41(3):666-74
pubmed: 26346639
Schizophr Res. 2016 Mar;171(1-3):176-81
pubmed: 26785807
Neurosci Biobehav Rev. 2018 Jul;90:381-399
pubmed: 29656029
Schizophr Res. 2015 Dec;169(1-3):214-216
pubmed: 26391282
Biol Psychiatry. 2015 Jan 15;77(2):147-57
pubmed: 25034946
Arch Gen Psychiatry. 2012 Mar;69(3):220-9
pubmed: 22393215
JAMA Psychiatry. 2018 Jun 1;75(6):613-622
pubmed: 29710118
J Clin Psychiatry. 2017 Jan;78(1):e28-e40
pubmed: 28129494
J Psychiatr Res. 2018 Jan;96:231-238
pubmed: 29121595
Can J Psychiatry. 2013 Jan;58(1):44-51
pubmed: 23327756
Psychiatry Res. 2014 Jan 30;215(1):52-60
pubmed: 24200216
Schizophr Res. 2017 Nov;189:19-26
pubmed: 28139360
Neuroimage Clin. 2017 Mar 06;14:622-628
pubmed: 28348953
Biol Psychiatry. 2015 Jun 1;77(11):951-8
pubmed: 25636178
Acta Psychiatr Scand. 2014 Jul;130(1):1-15
pubmed: 24611632
Schizophr Res. 2012 Dec;142(1-3):77-82
pubmed: 23043872
JAMA Psychiatry. 2015 Sep;72(9):882-91
pubmed: 26267151
Schizophr Res. 2017 Mar;181:6-12
pubmed: 27613509

Auteurs

Jean Addington (J)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. jmadding@ucalgary.ca.

Megan Farris (M)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.

Jacqueline Stowkowy (J)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.

Olga Santesteban-Echarri (O)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.

Paul Metzak (P)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.

Mohammed Shakeel Kalathil (MS)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH